2021/04/12 ALA-1000 Receive Decision of Grant from Federal Service for Intellectual Property (ROSPATENT) (Application No. 2019102895). Post author:alarpharm Post published:21 . 4 . 2021 Post category:Media releases You Might Also Like 2020/08/21 Alar Pharmaceuticals Inc. Completes Pre-IND Meeting with US FDA for ALA-3000 24 . 8 . 2020 2021/04/16 ALA-1000 Receive notice of allowance for patent registration from Korean Intellectual Property Office (Application No. 10-2019-7009185). 21 . 4 . 2021 2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021 2020/08/03 ALA -1000 Receive notice of patent allowance from the IP Australia. 25 . 8 . 2020 2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021
2020/08/21 Alar Pharmaceuticals Inc. Completes Pre-IND Meeting with US FDA for ALA-3000 24 . 8 . 2020
2021/04/16 ALA-1000 Receive notice of allowance for patent registration from Korean Intellectual Property Office (Application No. 10-2019-7009185). 21 . 4 . 2021
2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021
2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021
